Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2

Blood

Volumn 96, Issue 2, 2000, Pages 483-490

  Paul, Sujatha P ^a   Taylor, Lynn S ^a   Stansbury, Eryn K ^a   McVicar, Daniel W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; PERVANADATE; PHOSPHATASE; SIALIC ACID;

ARTICLE; DOWN REGULATION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; STEM CELL;

EID: 0034662163     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.483     Document Type: Article

References (48)

1. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62:124-132.
2. Simmons D, Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J Immunol. 1988;141:2797-2800.
3. Robertson MJ, Soiffer RJ, Freedman AS, et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia Blood. 1992;79:2229-2236.
4. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
5. Chen J, Zhou JH, Ball ED. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 × 22 (anti-CD33 × anti-CD64). Clin Cancer Res. 1995;1: 1319-1325.
6. Kelm S, Schauer R, Crocker PR. The Sialoadhesins - a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Glycoconj J. 1996;13:913-926.
7. Barnes YC, Skelton TP, Stamenkovic I, Sgroi DC. Sialylation of the sialic acid binding lectin sialoadhesin regulates its ability to mediate cell adhesion. Blood. 1999;93:1245-1252.
8. Razi N, Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci U S A. 1998;95:7469-7474.
9. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-2012.
10. Collins BE, Yang LJ, Mukhopadhyay G, et al. Sialic acid specificity of myelin-associated glycoprotein binding. J Biol Chem. 1997;272:1248-1255.
11. Dulac C, Tropak MB, Cameron-Curry P, et al. Molecular characterization of the Schwann cell myelin protein, SMP: structural similarities within the immunoglobulin superfamily. Neuron. 1992;8: 323-334.
12. Cornish AL, Freeman S, Forbes G, et al. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood. 1998;92:2123-2132.
13. Patel N, Linden EC, Altmann SW, et al. OB-BP1/ Siglec-6. A leptin-and sialic acid-binding protein of the immunoglobulin superfamily. J Biol Chem. 1999;274:22729-22738.
14. Floyd H, Ni J, Cornish AL, et al. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem. 2000;275:861-866.
15. Nicoll G, Ni J, Liu D, et al. Identification and characterization of a novel siglec, siglec-7 expressed by human natural killer cells and monocytes. J Biol Chem. 1999;274:34089-34095.
16. Kelm S, Schauer R. Sialic acids in molecular and cellular interactions. Int Rev Cytol. 1997;175:137-240.
17. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481-504.
18. Smith KGC, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med. 1998;187:807-811.
19. Unkeless JC, Jin J. Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol. 1997;9:338-343.
20. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904.
21. D'Ambrosio D, Hippen KL, Minskoff SA, et al. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science. 1995;268:293-297.
22. Blery M, Kubagawa H, Chen CC, et al. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc Natl Acad Sci U S A. 1998;95:2446-2451.
23. Binstadt BA, Brumbaugh KM, Dick CJ, et al. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity. 1996;5:629-638.
24. Burshtyn DN, Scharenberg AM, Wagtmann N, et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity. 1996;4: 77-85.
25. Doody GM, Justement LB, Delibrias CC, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269: 242-244.
26. Muta T, Kurosaki T, Misulovin Z, et al. A13-amino acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signaling. Nature. 1994;368:70-73.
27. Long EO, Burshtyn DN, Clark WP, et al. Killer cell inhibitory receptors: diversity, specificity, and function, Immunol Rev. 1997;155:135-144.
28. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol. 1997;27:660-665.
29. Cella M, Dohring C, Samaridis J, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cell involved in antigen processing. J Exp Med. 1997;185:1743-1751.
30. Kubagawa H, Burrows PD, Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci U S A. 1997;94:5261-5266.
31. Hayami K, Fukuta D, Nishikawa Y, et al. Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. J Biol Chem. 1997;272:7320-7326.
32. Meyaard L, Adema GJ, Chang C, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 1997;7:283-290.
33. Scharenberg AM, Kinet JP. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Cell. 1996;87:961-964.
34. Gergely J, Pecht I, Sarmay G. Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Immunol Lett. 1999;68:3-15.
35. Lorenz U, Ravichandran KS, Pei D, et al. Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murine T cells. Mol Cell Biol. 1994;14:1824-1834.
36. Stofega MR, Wang H, Ullrich A, Carter-Su C. Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association. J Biol Chem. 1998;273:7112-7117.
37. Blery M, Delon J, Trautmann A, et al. Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs. J Biol Chem. 1997;272:8989-8996.
38. Sarmay G, Koncz G, Pecht I, Gergely J. Cooperation between SHP-2, phosphatidyl inositol 3-kinase and phosphoinositol 5-phosphatase in the FcγRIIb mediated B cell regulation. Immunol Lett. 1999;68:25-34.
39. Baker MB, Podack ER, Levy RB. Perforin-and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant. 1995;1:69-73.
40. Huber M, Izzi L, Grondin P, et al. The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. J Biol Chem. 1999;274:335-344.
41. Cao MY, Huber M, Beauchemin N, et al. Regulation of mouse PECAM-1 tyrosine phosphorylation by the Src and Csk families of protein-tyrosine kinases. J Biol Chem. 1998;273:15765-15772.
42. Burshtyn DN, Yang W, Yi T, Long EO. A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1. J Biol Chem. 1997;272:13066-13072.
43. Burshtyn DN, Lam AS, Weston M, et al. Conserved residues amino-terminal of cytoplasmic tyrosines contribute to the SHP-1-mediated inhibitory function of killer cell Ig-like receptors. J Immunol. 1999;162:897-902.
44. Case RD, Piccione E, Wolf G, et al. SH-PTP2/ Syp SH2 domain binding specificity is defined by direct interactions with platelet-derived growth factor beta-receptor, epidermal growth factor receptor, and insulin receptor substrate-1-derived phosphopeptides. J Biol Chem. 1994;269:10467-10474.
45. Pei D, Wang J, Walsh CT. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Proc Natl Acad Sci U S A. 1996;93:1141-1145.
46. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 1992;12:835-846.
47. Gillooly DJ, Allen JM. The human high affinity IgG receptor (Fc gamma RI) signals through the immunoreceptor tyrosine-based activation motif (ITAM) of the gamma chain of Fc epsilon RI. Biochem Soc Trans. 1997;25:2153.
48. Taylor VC, Buckley CD, Douglas M, et al. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem. 1999;274: 11505-11512.